Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Family history of atherosclerotic vascular disease is associated with the presence of abdominal aortic aneurysm
Ye, Zi , Bailey, Kent R. , Austin, Erin , Kullo, Iftikhar J.

Vascular Medicine | November 13, 2015 | Volume: 21 | Issue: 1 | Pages: 41-46

10.1177/1358863x15611758 | PMID 26566659 Get It

We investigated whether family history (FHx) of atherosclerotic cardiovascular disease (ASCVD) was associated with presence of abdominal aortic aneurysm (AAA). The study cohort comprised of 696 patients with AAA (70±8 years, 84% men) and 2686 controls (68±10 years, 61% men) recruited from noninvasive vascular and stress electrocardiogram (ECG) laboratories at Mayo Clinic. AAA was defined as a transverse diameter of abdominal aorta ⩾ 3 cm or history of AAA repair. Controls were not known to have AAA. FHx was defined as having at least one first-degree relative with aortic aneurysm or with onset of ASCVD (coronary, cerebral or peripheral artery disease) before age 65 years. FHx of aortic aneurysm or ASCVD were each associated with presence of AAA after adjustment for age, sex, conventional risk factors and ASCVD: adjusted odds ratios (OR; 95% confidence interval): 2.17 (1.66–2.83, p < 0.01) and 1.31 (1.08–1.59, p < 0.01), respectively. FHx of ASCVD remained associated with AAA after additional adjustment for FHx of aortic aneurysm: adjusted OR: 1.27 (1.05–1.55, p = 0.01). FHx of ASCVD in multiple arterial locations was associated with higher odds of having AAA: the adjusted odds were 1.23 times higher for each additionally affected arterial location reported in the FHx (1.08–1.40, p = 0.01). Our results suggest both unique and shared environmental and genetic factors mediating susceptibility to AAA and ASCVD.
Reply to Dr. Merry’s Letter to the Editor
Dilli, Esma, Dodick, David, Dodick, David W.

Cephalalgia | November 13, 2015 | Volume: 36 | Issue: 9 | Pages: 910-910

10.1177/0333102415616875 | PMID 26566934 Get It

Re: Occipital nerve block for the short-term prevention of migraine
Merry, Stephen , Merry, Stephen P, Merry, Stephen P

Cephalalgia | November 13, 2015 | Volume: 36 | Issue: 9 | Pages: 909-909

10.1177/0333102415616874 | PMID 26566935 Get It

Confronting Drowsy Driving: The American Academy of Sleep Medicine Perspective
Chervin, Ronald D., Carden, Kelly A., Kirsch, Douglas B. , Kristo, David A., Malhotra, Raman K. , Ramar, Kannan , Rosen, Ilene M. , Weaver, Terri E. , Wise, Merrill S. , Morgenthaler, Timothy, Watson, Nathaniel F. , Morgenthaler, Timothy I. , Martin, Jennifer L.

Journal of Clinical Sleep Medicine | November 13, 2015 | Volume: 11 | Issue: 11 | Pages: 1335-1336

10.5664/jcsm.5200 | PMID 26414989 Get It

AASM Scoring Manual Version 2.2 Updates: New Chapters for Scoring Infant Sleep Staging and Home Sleep Apnea Testing
Berry, Richard B. , Gamaldo, Charlene E. , Harding, Susan M., Brooks, Rita, Lloyd, Robin M. , Vaughn, Bradley V. , Marcus, Carole L.

Journal of Clinical Sleep Medicine | November 13, 2015 | Volume: 11 | Issue: 11 | Pages: 1253-1254

10.5664/jcsm.5176 | PMID 26446251 Get It

Is Chemotherapy or Radiation Therapy in Addition to Surgery Beneficial for Locally Advanced Rectal Cancer in the Elderly? A National Cancer Data Base (NCDB) Study
Bergquist, John R. , Thiels, Cornelius A. , Shubert, Christopher R. , Habermann, Elizabeth B. , Hayman, Amanda V., Zielinski, Martin D. , Mathis, Kellie L. , Habermann, Elizabeth , Bergquist, John R , Thiels, Cornelius A

World Journal of Surgery | November 13, 2015 | Volume: 40 | Issue: 2 | Pages: 447-455

10.1007/s00268-015-3319-7 | PMID 26566779 Get It

AbstractIntroductionCurrent National Comprehensive Cancer Network guidelines for Stages II and III rectal cancer recommend neoadjuvant chemoradiation followed by curative intent surgery and adjuvant chemotherapy. It is unclear whether therapies in addition to surgery are truly beneficial in elderly patients. Our aim was to compare the survival of patients over 80 with Stages II and III rectal cancer undergoing curative intent surgery with or without additional therapy.Materials and methodsThe National Cancer Data Base (NCDB 2006–2011) was queried for patients over 80 with Stages II and III rectal cancer. The primary outcome was overall survival. Patients were stratified based upon therapy group. Univariate group comparisons were made. Unadjusted Kaplan–Meier and multivariable Cox proportional hazards modeling survival analyses were performed.ResultsThe query yielded 3098 patients over 80 with Stage II (N = 1566) or Stage III (N = 1532) disease. Approximately, half of the patients received surgery only. Kaplan–Meier analysis showed improved survival for patients receiving neoadjuvant and/or adjuvant therapy in addition to surgery, but there was no significant difference between those that received guideline concordant care (GCC), neoadjuvant chemoradiation only, or post‐operative chemotherapy only. Cox proportional hazard modeling identified age >90 and margin positivity as independent risk factors for decreased overall survival.ConclusionAnalysis of NCDB data for Stages II and III rectal cancer in patients over 80 shows a survival benefit of adjuvant and/or neoadjuvant therapy over surgery alone. There does not appear to be a difference in survival between patients who received neoadjuvant chemoradiation, post‐resection adjuvant chemotherapy, or GCC.
Myeloma today: Disease definitions and treatment advances
Rajkumar, S. Vincent

American Journal of Hematology | November 13, 2015 | Volume: 91 | Issue: 1 | Pages: 90-100

10.1002/ajh.24236 | PMID 26565896 Get It

There have been major advances in the diagnosis, staging, risk‐stratification, and management of multiple myeloma (MM). In addition to established CRAB (hypercalcemia, renal failure, anemia, and lytic bone lesions) features, new diagnostic criteria include three new biomarkers to diagnose the disease: bone marrow clonal plasmacytosis ≥60%, serum involved/uninvolved free light chain ratio ≥100, and >1 focal lesion on magnetic resonance imaging. MM can be classified into several subtypes based on baseline cytogenetics, and prognosis varies according to underlying cytogenetic abnormalities. A Revised International Staging System has been developed which combines markers of tumor burden (albumin, beta‐2 microglobulin) with markers of aggressive disease biology (high‐risk cytogenetics and elevated serum lactate dehydrogenase). Although the approach to therapy remains largely the same, the treatment options at every stage of the disease have changed. Carfilzomib, pomalidomide, panobinostat, daratumumab, elotuzumab, and ixazomib have been approved for the treatment of the disease. These drugs combined with older agents such as cyclophosphamide, dexamethasone, thalidomide, bortezomib, and lenalidomide dramatically increase the repertoire of regimens available for the treatment of MM. This review provides a concise overview of recent advances in MM, including updates to diagnostic criteria, staging, risk‐stratification, and management. Am. J. Hematol. 91:90–100, 2016. © 2015 Wiley Periodicals, Inc.
AASLD guidelines for treatment of chronic hepatitis B
Bzowej, Natalie, Chang, Kyong‐Mi , Hwang, Jessica , Jonas, Maureen M. , Murad, M. Hassan , Terrault, Norah A. , Murad, M Hassan , Chang, Kyong-Mi

Hepatology | November 13, 2015 | Volume: 63 | Issue: 1 | Pages: 261-283

10.1002/hep.28156 | PMID 26566064 Get It

Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
McMahon, Brian J. , Brown, Robert S., Wong, John B. , Ahmed, Ahmed T. , Farah, Wigdan , Almasri, Jehad , Alahdab, Fares , Benkhadra, Khalid, Mouchli, Mohamed A., Singh, Siddharth , Mohamed, Essa A. , Dabrh, Abd Moain Abu , Murad, M. Hassan , Mohammed, Khaled , Abu Dabrh, Abd Moain, Murad, Mohammad Hassan, Lok, Anna S. , Prokop, Larry J. , Wang, Zhen , Murad, M Hassan , Abu Dabrh, Abd Moain , Farah, Wigdan , Alahdab, Fares

Hepatology | November 13, 2015 | Volume: 63 | Issue: 1 | Pages: 284-306

10.1002/hep.28280 | PMID 26566246 Get It

Chronic hepatitis B viral (HBV) infection remains a significant global health problem. Evidence‐based guidelines are needed to help providers determine when treatment should be initiated, which medication is most appropriate, and when treatment can safely be stopped. The American Association for the Study of Liver Diseases HBV guideline methodology and writing committees developed a protocol a priori for this systematic review. We searched multiple databases for randomized controlled trials and controlled observational studies that enrolled adults ≥18 years old diagnosed with chronic HBV infection who received antiviral therapy. Data extraction was done by pairs of independent reviewers. We included 73 studies, of which 59 (15 randomized controlled trials and 44 observational studies) reported clinical outcomes. Moderate‐quality evidence supported the effectiveness of antiviral therapy in patients with immune active chronic HBV infection in reducing the risk of cirrhosis, decompensated liver disease, and hepatocellular carcinoma. In immune tolerant patients, moderate‐quality evidence supports improved intermediate outcomes with antiviral therapy. Only very low‐quality evidence informed the questions about discontinuing versus continuing antiviral therapy in hepatitis B e antigen‐positive patients who seroconverted from hepatitis B e antigen to hepatitis B e antibody and about the safety of entecavir versus tenofovir. Noncomparative and indirect evidence was available for questions about stopping versus continuing antiviral therapy in hepatitis B e antigen‐negative patients, monotherapy versus adding a second agent in patients with persistent viremia during treatment, and the effectiveness of antivirals in compensated cirrhosis with low‐level viremia. Conclusion: Most of the current literature focuses on the immune active phases of chronic HBV infection; decision‐making in other commonly encountered and challenging clinical settings depends on indirect evidence. (H epatology 2016;63:284–306)
Critical Appraisal and Review of Management Strategies for Severe Fibrosis During Penile Implant Surgery
Trost, Landon , Patil, Mukul, Kramer, Andrew

The Journal of Sexual Medicine | November 13, 2015 | Volume: 12 | Issue: Supplement_7 | Pages: 439-447

10.1111/jsm.12985 | PMID 26565574 Get It

Abstract Introduction Penile corporal fibrosis represents a challenging clinical scenario for surgeons placing penile prostheses (PP). Because of its rarity, a small number of series with limited follow-up have reported outcomes in this cohort. Aim The aim of this study was to perform a critical appraisal of the corporal excavation technique, discuss its relevance to contemporary practice, and review alternative surgical methods and outcomes. Methods A critical review was performed of the 2006 article by Montague and Angermeier, “Corporeal excavation: new technique for penile prosthesis implantation in men with severe corporeal fibrosis.” Notable inclusions and omissions were described, with emphasis placed on methodology and outcomes. A PubMed search from 1990 to June 2015 was then performed to review and summarize the literature on managing corporal fibrosis during PP surgery. Main Outcome Measures The main outcome measures used were the major contributions and limitations of the 2006 article describing outcomes of the corporal excavation technique. Results Corporal excavation is a relevant surgical technique for managing severe corporal fibrosis. Compared with alternatives, excavation achieves successful placement of PP without need for grafting and with few complications. The article was limited by several notable omissions including relevant patient demographic and disease characteristics, patient selection, and minimal descriptions of complications and outcomes. Alternative techniques include use of specialized dilators, counter incisions, reconstruction with graft placement, minimal scar tissue excision, and endoscopic resection. Because of limited data, no specific algorithm for managing corporal fibrosis can be prescribed. Conclusions Corporal fibrosis is a challenging clinical scenario and requires surgical experience and specialized techniques to manage appropriately. Corporal excavation represents one of several viable techniques, which may be chosen based on surgeon’s preference and clinical factors.